TG Therapeutics, Inc. Fundamental Analysis (NASDAQ: TGTX)
TG Therapeutics, Inc. (NASDAQ: TGTX) shows moderate financial fundamentals with a PE ratio of 86.99, profit margin of 11.81%, and ROE of 17.62%. The company generates $1.0B in annual revenue with strong year-over-year growth of 87.32%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 64.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze TGTX's fundamental strength across five key dimensions:
Efficiency Score
WeakTGTX struggles to generate sufficient returns from assets.
Valuation Score
ModerateTGTX shows balanced valuation metrics.
Growth Score
ExcellentTGTX delivers strong and consistent growth momentum.
Financial Health Score
ModerateTGTX shows balanced financial health with some risks.
Profitability Score
ModerateTGTX maintains healthy but balanced margins.
Key Financial Metrics
Is TGTX Expensive or Cheap?
P/E Ratio
TGTX trades at 86.99 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, TGTX's PEG of -1.15 indicates potential undervaluation.
Price to Book
The market values TG Therapeutics, Inc. at 15.94 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 50.15 times EBITDA. This signals the market has high growth expectations.
How Well Does TGTX Make Money?
Net Profit Margin
For every $100 in sales, TG Therapeutics, Inc. keeps $11.81 as profit after all expenses.
Operating Margin
Core operations generate 21.48 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.62 in profit for every $100 of shareholder equity.
ROA
TG Therapeutics, Inc. generates $6.66 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
TG Therapeutics, Inc. generates limited operating cash flow of $93.79M, signaling weaker underlying cash strength.
Free Cash Flow
TG Therapeutics, Inc. produces free cash flow of $93.04M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.61 in free cash annually.
FCF Yield
TGTX converts 0.85% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
86.99
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.15
vs 25 benchmark
P/B Ratio
Price to book value ratio
15.94
vs 25 benchmark
P/S Ratio
Price to sales ratio
11.05
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.32
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.50
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How TGTX Stacks Against Its Sector Peers
| Metric | TGTX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 86.99 | 31.66 | Worse (Expensive) |
| ROE | 17.62% | 501.00% | Weak |
| Net Margin | 11.81% | -3647.00% (disorted) | Strong |
| Debt/Equity | 1.32 | -0.30 (disorted) | Distorted |
| Current Ratio | 4.50 | 5.78 | Strong Liquidity |
| ROA | 6.66% | -262.00% (disorted) | Weak |
TGTX outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews TG Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
323925.19%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
227.92%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
90.77%
Industry Style: Defensive, Growth, Innovation
High Growth